Trump Administration's Executive Order Boosts Psychedelic Biotech Stocks, Including Compass Pathways (COMP360) and Definium Therapeutics (DT120)
Trump Administration Announces Executive Order to Address Mental Health Crisis
On April 18, 2026, U.S. President Donald Trump signed Executive Order 14401 to accelerate the development of treatments for Serious Mental Illness. This initiative aims to significantly improve access to treatment for patients, including military veterans, suffering from severe depression and Post-Traumatic Stress Disorder (PTSD). The White House has directed the Department of Health and Human Services (HHS) to establish a $50 million (USD$50M) matching fund through the Advanced Research Projects Agency for Health (ARPA-H) and to encourage joint investment with states to provide comprehensive support for basic research. This is a national commitment to provide innovative treatment alternatives to patients who have not responded to conventional treatments such as Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs).
FDA Priority Review Vouchers and Regulatory Relief
A key component of the executive order is the requirement for the Food and Drug Administration (FDA) to issue a 'National Priority Voucher' for psychedelic drugs designated as Breakthrough Therapies. Companies that obtain this voucher can expedite the FDA's new drug approval review process by several months, accelerating the commercialization of new drugs. Furthermore, the Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) have been instructed to promptly reschedule drugs after Phase 3 clinical trials are completed and FDA approval is granted. By providing official support and establishing expedited regulatory pathways for psychedelic drugs, regulatory uncertainty in the market has been significantly reduced.
Key Beneficiaries and Phase 3 Pipeline Status
Compass Pathways (COMP) and Definium Therapeutics (DFTX), which are at the forefront of clinical development, are expected to be the biggest beneficiaries. Compass Pathways has completed Phase 3 clinical trials for COMP360, a synthetic psilocybin targeting the serotonin 2A (5-HT2A) receptor, and is preparing to submit a New Drug Application (NDA) to the FDA. Definium Therapeutics, formerly MindMed, is actively conducting Phase 3 trials for DT120, a synthetic LSD derivative, targeting Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD). In addition, Helus Pharma (HELP) is seeking market entry through Phase 2/3 trials of HLP003 (Deuterated Psilocin) and HLP004 (Deuterated DMT), which are serotonin agonists.
$13 Billion Psychedelic Market Forecast
The global psychedelic therapeutics market is projected to grow rapidly from approximately $3.4 billion to $7.4 billion in 2026 to a maximum of $13.7 billion (USD$13.7B) in 2030. Investor sentiment, which had cooled after the FDA Advisory Committee (AdComm) rejected Lykos Therapeutics' PTSD treatment, a MDMA combination drug, in August 2024 with a 10-to-1 vote against efficacy and a 9-to-2 vote against safety, is now rapidly reversing due to this easing of regulations. Johnson & Johnson (JNJ)'s Spravato, an esketamine-based antidepressant, has already demonstrated commercial success with annual sales of hundreds of millions of dollars. Furthermore, as AbbVie (ABBV) has entered into a co-development agreement with Gilgamesh Pharmaceuticals for up to $1.95 billion, technology transfer and mergers and acquisitions (M&A) activities among large pharmaceutical companies are expected to become more active.
This executive order is a pivotal moment in reducing the regulatory risk premium in the global psychedelic market, which is estimated at $3.4 billion in 2026. In the short term, the FDA review period for leading pipeline assets such as Compass Pathways (COMP)'s COMP360 (psilocybin, Phase 3) and Definium Therapeutics (DFTX)'s DT120 (LSD derivative, Phase 3) is expected to be shortened by at least four months through the National Priority Voucher. In the medium to long term, this will serve as a catalyst for M&A and licensing deals among large pharmaceutical companies such as AbbVie (ABBV) and Otsuka, in the field of neuroplasticity-based treatments for mental disorders, pioneered by Johnson & Johnson (JNJ)'s Spravato. Furthermore, the DEA's mandatory requirement for prompt rescheduling of controlled substances will maximize physician prescribing convenience, significantly increasing the potential for early commercial sales.